摘要
目的探讨多巴丝肼联合米氮平在帕金森病治疗中的应用价值。方法选取94例帕金森病患者为研究对象,以随机数字表法分为对照组47例,观察组47例。两组患者均给予心理疏导、运动训练,对并发症予以对症治疗。对照组加用多巴丝肼,观察组在对照组基础上联合米氮平治疗,观察两组患者治疗前后帕金森病统一评分量表(UPDRS)、汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)变化及治疗期间不良反应发生情况。结果治疗前两组UPDRS评分差异无统计学意义,治疗后均有下降,UPDRSⅠ、UPDRSⅡ、UPDRSⅢ评分,观察组同对照组比较,明显较低,差异有统计学意义(P<0.05)。治疗前两组心理状态差异无统计学意义,治疗后均有改善。观察组与对照组HAMD、HAMA评分比较,差异有统计学意义(P<0.05);治疗期间不良反应发生率观察组为14.89%,同对照组8.51%比较,差异无统计学意义(P>0.05),两组均未出现严重不良反应。结论多巴丝肼联合米氮平治疗帕金森病,疗效确切,安全性较高,且可有效改善患者心理状态。
Objective To investigate the application value of benserazide combined with mirtazapine in the treatment of parkinson's disease. Methods 94 patients with parkinson' s disease were selected as the research object,and were randomly divided into the control group of 47 cases and the observation group of 47 cases,Two groups of patients were given psychological counseling,exercise training,symptomatic treatment of complications,the control group was treated with levodopa and benserazide hydrochloride,the observation group in the control group based on the combined treatment of mirtazapine,The changes of parkinson disease unified score scale( UPDRS),Hamilton Anxiety Scale(HAMA) and Hamilton Depression Scale(HAMD) before and after treatment and adverse reactions during treatment were observed in the two groups. Results there was no significant difference in UPDRS scores between the two groups before treatment,but decreased after treatment. The scores of UPDRS I,UPDRS II and UPDRS III scores in the observation group were significantly lower than those in the control group,with statistical difference( P < 0. 05). There was no significant difference in psychological status between the two groups before treatment,and improved after treatment. The scores of HAMD and HAMA in the observation group were significantly lower than those in the control group,with statistical difference( P < 0. 05). The incidence of adverse reactions in the observation group was 14. 89% compared with 8.51% in the control group,the difference was not statistically significant( P > 0. 05),there were no serious adverse reactions in the two groups. Conclusion Levodopa and benserazide hydrochloride combined with mirtazapine in the treatment of Parkinson's disease has better curative effect and high safety,and can effectively improve the psychological status of patients.
出处
《中国临床保健杂志》
CAS
2018年第1期58-61,共4页
Chinese Journal of Clinical Healthcare
基金
浙江省医药卫生一般研究计划(2015KYB451)
关键词
帕金森病
苄丝肼
左旋多巴
米氮平
治疗结果
Parkinson disease
Benserazide
Levodopa
Mirtazapine
Treatment outcome
